Journal
PHARMACOGENOMICS
Volume 16, Issue 18, Pages 2019-2034Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.145
Keywords
folate metabolism; homocysteine; Indians; methotrexate; pharmacogenomics; pharmacokinetics
Categories
Funding
- Council for Scientific and Industrial Research, New Delhi, India
- Lady Tata Memorial Trust, Mumbai, India
- NIH [R01CA132946, R21CA155524, AR060861, AR057781, AR065964, AI071651]
- Rheumatology Research Foundation
- Cure JM Foundation
- Mayo Clinic Foundation
- Foundation of Minnesota
Ask authors/readers for more resources
Aim: We evaluated the pharmacogenetic influence of genetic polymorphisms in folate pathway genes in Indian rheumatoid arthritis patients receiving methotrexate (MTX). Patients & methods: Twelve polymorphisms within nine folate pathway genes were analyzed for association with MTX response in 322 Indian rheumatoid arthritis (RA) patients and MTX pharmacokinetics in 94 RA patients. Results: Polymorphisms in GGH, SHMT1 and TS were associated with MTX-related adverse events while SNPs in MTHFR and RFC1/SLC19A1 were associated with MTX efficacy. TS5' UTR and SHMT1 polymorphisms were associated with higher plasma levels of MTX. Conclusion: Polymorphisms in folate-MTX pathway genes contribute to MTX response and affect MTX concentrations in Indian RA patients. A toxicogenetic index could identify patients who develop adverse events to MTX.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available